Rapport Therapeutics Appoints Chief Financial Officer

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of industry veteran Troy Ignelzi as Chief Financial Officer, effective November 1, 2023.

"We are thrilled to welcome Troy to the Rapport executive team during this time of rapid progress for our company," said Abraham Ceesay, Chief Executive Officer of Rapport. "With his extensive experience guiding life science companies through major value creation milestones, as well as his demonstrated ability in raising and structuring financings for growth-oriented biotech companies, Troy is the ideal addition to Rapport. As we work to advance and expand our portfolio and ultimately deliver better treatment options for patients living with serious neurological disorders, Troy's expertise of the biotech financial landscape will help propel us forward."

Mr. Ignelzi joins Rapport with nearly two decades of financial leadership experience in the biotech and pharmaceuticals sectors. Over the course of his career, Mr. Ignelzi has raised an impressive $4 billion-plus in capital for life science companies. Most recently, he was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company's IPO and multiple follow-on financings. Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals. He has a long track record of experience in the sector, having started out at Eli Lilly and then moving on to roles of increasing responsibility at companies including Esperion Therapeutics and the former Insys Therapeutics. Previously, Mr. Ignelzi served on the board of CinCor Pharma, Inc., where he advised on the company's sale to AstraZeneca in early 2023. He currently serves on the boards of Vedanta Biosciences and Abivax. He is a graduate of Ferris State University, where he earned his B.S. in accounting.

"There is no question that Rapport has tapped into a potentially transformative way to address unmet need in patients with neurological disorders," said Mr. Ignelzi. "Rapport's innovative scientific approach to precision neuromedicine, which creates tremendous opportunity to dramatically improve patient outcomes, is incredibly exciting to me and also signals the potential for significant company growth in the future."

About Rapport (www.rapportrx.com)

Rapport pursues precision neuromedicine in an effort to give patients better alternatives to current treatments for neurological diseases, which often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance and discontinuation. By more precisely targeting the neural circuits and cell types where diseases originate, Rapport's approach has the potential to reduce the unwanted drug-target interactions that lead to these issues. The company's platform, built and refined over the past decade by its founding scientific team, achieves precision through the discovery and targeting of receptor-associated proteins, or RAPs, which display regional or neural circuit-specific expression. The company has ongoing clinical programs in seizure and psychiatric disorders.